Cardiovascular function in nonclinical drug safety assessment: Current issues and opportunities

International Journal of Toxicology

Volumn 30, Issue 3, 2011, Pages 272-286

  Sarazan, R Dustan ^a   Mittelstadt, Scott ^b   Guth, Brian ^c   Koerner, John ^d   Zhang, Joanne ^d   Pettit, Syril ^e  

^a Data Sciences International   (United States)

^b ABBOTT LABORATORIES   (United States)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e ILSI HEALTH AND ENVIRONMENTAL SCIENCES INSTITUTE   (United States)

Author keywords

cardiovascular; hemodynamics; safety assessment

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DOFETILIDE; ITRACONAZOLE; MOXIFLOXACIN; NORADRENALIN UPTAKE INHIBITOR;

ARTERIAL PRESSURE; ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR FUNCTION; DRUG INDUSTRY; DRUG SAFETY; ELECTROCARDIOGRAM; HEART CONTRACTION; HEART HEMODYNAMICS; HEART OUTPUT; HEART RATE; HEART VENTRICLE CONTRACTILITY; HUMAN; NONHUMAN; PRESSURE TRANSDUCER; QT INTERVAL; QT PROLONGATION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; VASCULAR RESISTANCE;

CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; DRUG THERAPY; HEART; HEMODYNAMICS; HUMANS;

EID: 79960662989     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1177/1091581811398963     Document Type: Article

References (45)

1. Guidelines for General Pharmacology Studies. Tokyo: Japanese Ministry of Health & Welfare ; 1991 :
2. Kinter LB, Valentin J-P. Safety pharmacology and risk assessment. Fund Clin Pharmacol. 2002 ; 16 (3). 175-182 (Pubitemid 35304418)
3. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Eng J Med. 2007 ; 357 (21). 2109-2122 (Pubitemid 350146106)
4. Nissen SE, Wolski K. Effects of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Eng J Med. 2007 ; 356 (24). 2457-2471 (Pubitemid 46919772)
5. Bass AS, Kinter L, Williams P. Origins, practices and future of safety pharmacology. J Pharmacol Toxicol Methods. 2004 ; 49 (3). 145-151 (Pubitemid 38686652)
6. Committee for Proprietary Medicinal Products Points to Consider: the Assessment of the Potential for QT Prolongation by Non-Cardiovascular Medicinal Products. The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit, London.. 1997 ;:
7. Anon. ICHS7A: Safety Pharmacology Studies for Human Pharmaceuticals. 2000. http://private.ich.org/LOB/media/MEDIA504.pdf. Accessed February 2011
8. Anon. ICHS7B: The non-clinical evaluation of the potential for delayed ventricular repolarization (QT Interval Prolongation) by Human Pharmaceuticals. 2005. http://private.ich.org/LOB/media/MEDIA504.pdf. Accessed February 2011.
9. Cochran WG, Cox GM Experimental Designs. New York: Wiley and Sons ; 1957 :
10. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002 ; 360 (9349). 1903-1913 (Pubitemid 35472129)
11. Beglinger LJ, Adams WH, Paulson H, et al. Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease. J Clin Psychopharmacol. 2009 ; 29 (5). 484-487
12. Chan CC, Reid CM, Aw TJ, Liew D, Haas SJ, Krum H. Do COX-2 inhibitors raise blood pressure more than non-selective NSAIDS and placebo? An updated meta-analysis. J Hypertens. 2009 ; 27 (12). 2332-2341
13. Reinhart GA, Fryer RM, Osinski MA, Polakowski JA, Cox BF, Gintant GA. Predictive, non-GLP models of secondary pharmacodynamics: putting the best compounds forward. Curr Opin Chem Biol. 2005 ; 9 (4). 392-399 (Pubitemid 41019686)
14. Cox RH. Influence of pentobarbital anesthesia on cardiovascular function in trained dogs. Am J Physiol. 1972 ; 223 (3). 651-659
15. Van Citters RL, Franklin DL. Telemetry of blood pressure in free-ranging animals via an intravascular gauge. J Appl Physiol. 1966 ; 21 (5). 1633-1636
16. Sarazan RD, Schweitz KTR. Standing on the shoulders of giants: Dean Franklin and his remarkable contributions to physiological measurements in animals. Adv Physiol Educ. 2009 ; 33 (3). 144-156
17. Sarazan RD. Chronically instrumented conscious dog model in cardiovascular toxicology studies. Tox Methods. 1993 ; 3 (3). 195-211
18. Sarazan RD Comprehensive Toxicology. Bishop SP Kerns WD, ed. Oxford, England: Pergamon Press ; 1997: 137-150.
19. Taylor GL, Patela B, Sullivan AT. Evaluation of blood flow parameters in addition to blood pressure and electrocardiogram in the conscious telemetered beagle dog. J Pharmacol Toxicol Methods. 2007 ; 56 (2). 212-217 (Pubitemid 47375126)
20. O'Rourke MF. Vascular impedance in studies of arterial and cardiac function. Physiol Rev. 1982 ; 62 (2). 570-623
21. Francine EA, Martel E, Champeroux P, Richard S, Rieux E, Singer D. Evaluation of multifrequency repeaters for record of cardiovascular parameters in group housed dogs. J Pharmacol Toxicol Methods. 2007 ; 56 (2). e21
22. Katz AM Physiology of the Heart. New York: Raven Press ; 1977: 225.
23. Suga H, Sagawa K, Shoukas AA. Load independence of the instantaneous pressure-volume ratio of the canine left ventricle and effects of epinephrine and heart rate on the ratio. Circ Res. 1973 ; 32 (3). 314-322
24. Slordahl L, Spigset O. Heart failure induced by non-cardiac drugs. Drug Saf. 2006 ; 29 (7). 567-586 (Pubitemid 44175028)
25. Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet. 2001 ; 357 (9270). 1766-1767 (Pubitemid 32524211)
26. Markert M, Klumpp A, Trautmann T, Mayer K, Stubhan M, Guth B. The value added by measuring myocardial contractility 'in vivo' in safety pharmacological profiling of drug candidates. J Pharmacol Toxicol Methods. 2007 ; 56 (2). 203-211 (Pubitemid 47381502)
27. Norton K, Iacono G, Venzina A. Assessment of the pharmacological effects of inotropic drugs on left ventricular pressure and contractility: an evaluation of the QA interval as an indirect indicator of cardiac inotropism. J Pharmacol Toxicol Methods. 2009 ; 60 (2). 193-197
28. Adeyemi O, Roberts S, Harris J, West H, Shome S, Dewhurst M. QA interval as an indirect measure of cardiac contractility in the conscious telemeterised rat: model optimisation and evaluation. J Pharmacol Toxicol Methods. 2009 ; 60 (2). 159-166
29. Miura T, Miyazaki S, Guth BD, Kambayashi M, Ross J. Influence of the force-frequency relation on left ventricular function during exercise in conscious dogs. Circulation. 1992 ; 86 (2). 563-571
30. Sarazan RD. Validation of a digital data acquisition and analysis system in a cardiovascular toxicology laboratory. Tox Methods. 1993 ; 4 (4). 274-291
31. Sarazan D, Pettit S, Berridge B. Towards an integrated approach to cardiovascular safety assessment: the HESI Committee on Cardiac Safety. Presentation at the Safety Pharmacology Society Annual Meeting ; 2009 Strasbourg, France ; 2009..
32. Sarazan RD, Starke WA, Krause GF, Garner HE. Cardiovascular effects of detomidine, a new ?2-adrenoceptor agonist, in the conscious pony. J Vet Pharmacol Therap. 1989 ; 12 (4). 378-388
33. Henriques TA, Beck TW, Douglas CL, et al. Left thoracotomy surgical approach for chronic instrumentation in dogs and monkeys providing high-quality electrocardiogram signals. J Pharmacol Toxicol Methods. 2010 ; 62 (2). 136-142
34. Hanton G, Eder V, Rochefort G, Bonnet P, Hyvelin J-M. Echocardiography, a non-invasive method for the assessment of cardiac function and morphology in preclinical drug toxicology and safety pharmacology. Expert Opin Drug Metab Toxicol. 2008 ; 4 (6). 681-696 (Pubitemid 352003193)
35. Anon. ICHS9: Nonclinical Evaluation for Anticancer Pharmaceuticals. 2009. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM129110.pdf. Accessed February 2011.
36. Manual of Canine and Feline Cardiology. 3 rd ed. Tilley LP Goodwin JK, ed. Philadelphia: W.B. Saunders ; 2001 :
37. Mitchell AZ, McMahon C, Beck TW, Sarazan RD. Sensitivity of two noninvasive blood pressure measurement techniques compared to telemetry in cynomolgus monkeys and beagle dogs. J Pharmacol Toxicol Methods. 2010 ; 62 (1). 54-63
38. Rushmer RF Cardiovascular Dynamics. 2 nd ed. Philadelphia: W.B. Saunders ; 1961: 135-136.
39. Schmelting B, Niehoff M, Egner B, Korte SH, Weinbauer GF. High definition oscillometry: a novel technique for non-invasive blood pressure monitoring in the cynomolgus monkey (macaca fascicularis). J Med Primatol. 2009 ; 38 (5). 293-301
40. Rajamani S, Eckhardt LL, Valdivia CR, et al. Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol. 2006 ; 149 (5). 481-489 (Pubitemid 44658508)
41. Chiang AY, Holdsworth DL, Leishman DJ. A one-step approach to the analysis of the QT interval in conscious telemeterized dogs. J Pharmacol Toxicol Methods. 2006 ; 54 (2). 183-188 (Pubitemid 44404073)
42. Vargas HM, Bass AS, Breidenbach A, et al. Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics. J Pharmacol Toxicol Methods. 2008 ; 58 (2). 72-76
43. McMahon C, Mitchell AZ, Klein JL, Jenkins AC, Sarazan RD. Evaluation of blood pressure measurement using a miniature blood pressure transmitter with jacketed external telemetry in cynomolgus monkeys. J Pharmacol Toxicol Methods. 2010 ; 62 (2). 127-135
44. Anon. ICHE14: Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. 2005. http://private.ich. org/LOB/media/MEDIA1476.pdf. Accessed February 2011.
45. Chiang AY, Bass AS, Cooper MM, Engwall MJ, Menton RG, Thomas K. ILSI-HESI cardiovascular safety subcommittee dataset: an analysis of the statistical properties of QT interval and rate-corrected QT interval (QTc). J Pharmacol Toxicol Methods. 2007 ; 56 (2). 95-102 (Pubitemid 47375129)